RAASi Therapy, Diabetes, and Hyperkalemia: Halting Therapy is NOT the Only Option
Faculty: George L. Bakris, MD, Biff F. Palmer, MDOct. 10, 2021
View this accredited e-learning program with a focus on heart failure at our partner website ReachMD, a leading online learning platform for physicians and other healthcare professionals
Patients diagnosed with diabetes, hypertension, and chronic kidney disease can benefit from RAAS inhibitors, provided that certain guidelines are followed.
Join Drs. George Bakris and Biff Palmer in a review of RAAS inhibitor titration dosage, obstacles to optimization of the dosing of these therapies in patients with comorbidities, and the use of potassium binders for the management of hyperkalemia as an alternative to discontinuing RAASi therapy.
Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- Biff F. Palmer, MD, Professor of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA
- George L. Bakris, MD, Professor of Medicine, Director, Am Heart Assoc. Comprehensive Hypertension Center, University of Chicago Medicine, Chicago, IL, USA
This activity is supported by an independent educational grant from Vifor Pharma.